A very useful discussion started by @stockrock on commercial potential for aGVHD and implications for the cash runway. The one part of my knowledge that is poor is the economics of health care in the US. Specifically of the $300,000 some have said we may get per treatment how much of this comes from insurer/govt/patient? And what are the implications for eventual market penetration do things like the percentage of patients without adequate health insurers have in terms of limiting penetration?
Market opportunity aGVHD, page-36
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.5¢ |
Change
-0.015(1.49%) |
Mkt cap ! $1.136B | |||
| Open | High | Low | Value | Volume |
| $1.02 | $1.02 | 99.5¢ | $2.005M | 1.991M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 14424 | 99.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.00 | 63643 | 1 |
View Market Depth
| Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |